Does trastuzumab-emtansine have better cardiac safety profile in contrast to trastuzumab?

Journal of B.U.ON.

Volumn 18, Issue 3, 2013, Pages 801-

  Sendur, Mehmet Ali Nahit ^a   Aksoy, S ^b   Ozdemir, Y ^a   Zengin, N ^a   Altundag, K ^b  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PACLITAXEL; TRASTUZUMAB; TRASTUZUMAB EMTANSINE;

BREAST CANCER; CANCER SURVIVAL; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG TREATMENT FAILURE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INCIDENCE; LETTER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HEART DISEASES; HUMANS; MAYTANSINE; PROGNOSIS; RECEPTOR, ERBB-2;

EID: 84885746124     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Seidman A, Hudis C, Pierri MK et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20:1215-1221. (Pubitemid 34177427)
2. Verma S, Miles D, Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367:1783-1791.
3. Krop IE, Lo Russo P, Miller KD et al. A phase II study of trastuzumab emtansive in petients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane and capecitabine. J Clin Oncol 2012; 30:3234-3241.
4. Burris HA 3rd, Rugo HS, Vukelja SJ et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011;29:398-405.
5. Hurvitz S, Dirix L, Kocsis J et al. Trastuzumab emtansine (T-DM1) vs trastuzumab plus docetaxel (H+T) in previously untreated HER2-positive metastatic breast cancer (MBC): primary results of a randomized, multicenter, open-label phase II study (TDM4450g/B021976). Eur J Cancer 2011; 47(Suppl 330): 5001 (abstr).